F-Tryptophan PET/CT in Human Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBarbara Ann Karmanos Cancer Institute
About this trial
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
Eligibility criteria
Qualifiers
Age ≥18 years.
Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
Women of childbearing potential must not be pregnant or breastfeeding.
Disqualifiers
Patients who are pregnant or lactating are excluded.
Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
Tumor surgery or radiation within 1 month prior to the PET scan
Tumor-directed therapy within 3 months to the area of planned imaging.
Trial design
Treatments tested in this trial
- 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Barbara Ann Karmanos Cancer Institute
Lead sponsor
Washington University School of Medicine
Collaborator
Source ClinicalTrials.gov